This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

OmniSpirant Limited


OmniSpirant Limited was founded in 2016 by Mr Gerry McCauley, a pharmacist and inventor of the first-in-class inhaled regenerative gene therapy platform technology (OmniSomes). OmniSpirant identified and have developed differential abilities in working with surface engineered extracellular vesicles (EVs) and harnessing them to carry genetic information to target cells and tissues to enhance the treatment of chronic lung diseases. In pulmonary medicine, delivering RNA and DNA gene therapy cargoes to the lung is especially challenging with over 25 years of attempts and failures in the case of cystic fibrosis. OmniSpirant believe the OmniSome technology is the ‘Rosetta stone’, a key enabling platform to develop multiple lung targeted gene therapies. OmniSpirant received EU funding in 2018 via the Horizon 2020 SME Instrument to develop advanced therapies for the treatment of cystic fibrosis. OmniSpirant also received the EU seal of excellence in 2020 & 2022. OmniSpirant’s expert team of researchers are based in our of state-of-the-art laboratories in Galway, Ireland. The company is currently raising a €45 million Series A round to progress it’s pipeline and the clinical translation of lead assets.